These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19226501)

  • 1. Induction of a melanoma-specific antibody response by a monovalent, but not a divalent, synthetic GM2 neoglycopeptide.
    Bay S; Fort S; Birikaki L; Ganneau C; Samain E; Coïc YM; Bonhomme F; Dériaud E; Leclerc C; Lo-Man R
    ChemMedChem; 2009 Apr; 4(4):582-7. PubMed ID: 19226501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.
    Retter MW; Johnson JC; Peckham DW; Bannink JE; Bangur CS; Dresser K; Cai F; Foy TM; Fanger NA; Fanger GR; Woda B; Rock KL
    Cancer Res; 2005 Jul; 65(14):6425-34. PubMed ID: 16024647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
    Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
    Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
    Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
    Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
    Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies.
    Ohta S; Igarashi S; Honda A; Sato S; Hanai N
    Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
    Livingston PO; Calves MJ; Natoli EJ
    J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides from Camplyobacter jejuni.
    Ritter G; Fortunato SR; Cohen L; Noguchi Y; Bernard EM; Stockert E; Old LJ
    Int J Cancer; 1996 Apr; 66(2):184-90. PubMed ID: 8603809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental and clinical studies with active specific immunotherapy.
    Livingston PO
    Prog Clin Biol Res; 1989; 288():309-21. PubMed ID: 2654953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy.
    Lo-Man R; Bay S; Vichier-Guerre S; Dériaud E; Cantacuzène D; Leclerc C
    Cancer Res; 1999 Apr; 59(7):1520-4. PubMed ID: 10197623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoenzymatic synthesis of GM3 and GM2 gangliosides containing a truncated ceramide functionalized for glycoconjugate synthesis and solid phase applications.
    Jacques S; Rich JR; Ling CC; Bundle DR
    Org Biomol Chem; 2006 Jan; 4(1):142-54. PubMed ID: 16358009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical Synthesis of GM2 Glycans, Bioconjugation with Bacteriophage Qβ, and the Induction of Anticancer Antibodies.
    Yin Z; Dulaney S; McKay CS; Baniel C; Kaczanowska K; Ramadan S; Finn MG; Huang X
    Chembiochem; 2016 Jan; 17(2):174-80. PubMed ID: 26538065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganglioside vaccines with emphasis on GM2.
    Livingston P
    Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
    Livingston PO; Natoli EJ; Calves MJ; Stockert E; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1987 May; 84(9):2911-5. PubMed ID: 3472242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
    Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
    Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E
    Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.
    Takahashi T; Johnson TD; Nishinaka Y; Morton DL; Irie RF
    J Invest Dermatol; 1999 Feb; 112(2):205-9. PubMed ID: 9989797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gangliosides, Ab1 and Ab2 antibodies III. The idiotype of anti-ganglioside mAb P3 is immunogenic in a T cell-dependent manner.
    López-Requena A; Bestagno M; Mateo de Acosta C; Cesco-Gaspere M; Vázquez AM; Pérez R; Burrone OR
    Mol Immunol; 2007 Apr; 44(11):2915-22. PubMed ID: 17316805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.
    Yamaguchi H; Furukawa K; Fortunato SR; Livingston PO; Lloyd KO; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1990 May; 87(9):3333-7. PubMed ID: 2159145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel linker methodology for the synthesis of tailored conjugate vaccines composed of complex carbohydrate antigens and specific TH-cell peptide epitopes.
    Dziadek S; Jacques S; Bundle DR
    Chemistry; 2008; 14(19):5908-17. PubMed ID: 18478617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.